Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §2

Tendon, ligament and musculoskeletal soft-tissue injury — evidence across compounds

Every compound the Institute assesses in tendon, ligament and musculoskeletal soft-tissue injury, with its certainty rating.

Document identifier
CEI-IN-22/2
Series
Indication assessment
Version
2.3
Published
21 Aug 2024
Last reviewed
21 Aug 2024
Next review
21 Aug 2026
Identifier
10.71829/cei.ind.22
Certainty
Not rated
Cycle
2024 Q3
ICD-11
FB50
Category
Musculoskeletal

§2Evidence across compounds

Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.

Table 1. Compounds assessed in tendon, ligament and musculoskeletal soft-tissue injury, ordered by certainty.

CompoundEffect as recordedInterval as reportedCertaintyTrials
BPC-157Synthetic pentadecapeptide derived from a gastric juice…No randomised controlled human trial identifiedVery low0
TB-500Acetylated heptapeptide fragment of thymosin beta-4No randomised controlled human trial identifiedVery low0
Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here.
Compounds assessed in Soft-tissue injuryPoint estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.20.40.6Standardised direction and relative magnitudeCompoundEffect as recordedBPC-157Very low certaintyNo randomised controlled human…TB-500Very low certaintyNo randomised controlled human…
Moderate or high certaintyLow or very low certainty
Figure 1. Illustrative. Compounds assessed in this indication, plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision rather than published confidence intervals.

§2.1Syntheses bearing on this indication

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
  2. Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.